When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?

British Journal of Urology

Volumn 79, Issue 5, 1997, Pages 770-776

  Haukaas, S ^a,b,c,d   Roervik, J ^a,b,c,d   Halvorsen, O J ^a,b,c,d   Foelling, M ^a,b,c,d  

^a Department of Surgery   (Norway)

^b Department of Radiology ^*  (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bone scintigraphy; Prognosis; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER;

EID: 0031395278     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1997.00141.x     Document Type: Article

References (28)

1. Breschet G, Recherches anatomiques, physiologiques et pathologiques sur le systeme veineux et specialement sur les cavaux veineux des os. Villaret et Cie, Paris, 1828-1832
2. Schaffer DL, Pendergrass HP. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate. Radiology 1976; 121: 431-4
3. Corcoran RJ, Trall JH, Kyle RW, Kaminski RJ, Johnson MD. Solitary abnormalities in bone scans of patients with extraosseus malignancies. Radiology 1976; 121: 663-7
4. Chybowski FM, Larson Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-8
5. Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in staging and monitoring of patients with prostatic cancer. Br J Urol 1992; 70: 295-8
6. Pantelides ML, Bowman PS, George NJR. Levels of prostate specific antigen that predict skeletal spread in prostate cancer. Br J Urol 1992; 70: 299-303
7. Noldus J, Stamey TA. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. J Urol 1996; 155: 232-7
8. Mostofi FK, Sesterhenn IA, Sobin LH. Histological typing of prostate tumours. In International Histological Classification of Tumours, No. 22, World Health Organization, Geneva, 1980
9. Schroeder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992; Suppl 4: 129-38
10. Vessella RL, Noteboom J, Lange PH. Evaluation of the Abott IMx automated immunoassay of prostate specific antigen. Clin Chem 1992; 38: 2044-54
11. Altman DG. Diagnostic tests. In Practical Statistics for Medical Research. London: Chapman and Hall, 1995: 409-11
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53: 457-81
13. Cox DR. Regression model and life tables. J Roy Stat Soc 1972; B 34: 187-220
14. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63
15. 1 prostate cancer. Cancer Res 1985; 45: 886-91
16. Stamey TA,Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific-antigen as a serum marker for adenocarcinoma of the prostate. New Engl J Med 1987; 317: 909-16
17. Armitage TG, Cooper EH, Newling DWW, Robinson MRG, Appleyard I. The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancer. Br J Urol 188; 62: 584-9
18. Stamey TA, Kabalin JN, McNeal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-83
19. Partin AW, Carter HB, Chan DW et al Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143; 747-52
20. Oesterling JE, Chan DW. Epstein JI et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988; 139: 766-72
21. Edson Pontes J, Wajsman Z, Huben RP, Wolf RM, Englander LS. Prognostic factors in localized prostatic carcinoma. J Urol 1985; 134: 1137-9
22. DeAntoni EP, Crawford ED. Prostate cancer awareness week. Education, service and research in a community setting. Cancer 1995; 75: 1874-9
23. Bostwick DG, Qian J, Bergstralh E et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155: 1361-7
24. Lee SE, Currin SM, Paulson DF, Walther PJ. Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol 1988; 140: 769-74
25. McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 1992; 23: 258-66
26. Kuriyama M, Wang MC, Lee CL et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 1981; 41: 3874-6
27. Svanholm H. Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and specific acid phosphatase. Acta Pathol Microbiol Immunol Scand (A) 1986; 94: 7-12
28. Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202